MalarVx licenses HDT Bio's repRNA/LION™ Technology for Novel Malaria Vaccine

HDT Bio's LION™ platform to support malaria vaccine development by MalarVx SEATTLE, Jan. 15, 2025 /PRNewswire/ -- MalarVx, Inc., a clinical-stage vaccine company, is proud to announce a license to HDT Bio's proprietary self-amplifying replicon RNA (repRNA) and lipid nanoparticle (LION™)...